View clinical trials related to Hemorrhagic Fever, Ebola.
Filter by:The human monoclonal antibody (mAb), ansuvimab (mAb114), will be provided to Ebola-infected patients as either a treatment or as PEP under expanded access. Ansuvimab is administered at 50 mg/kg as a single intravenous (IV) infusion
Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).